In the literature, there are few high-throughput screens or even methods for high-throughput screens of recombinant adeno-associated virus (rAAV) production despite potential benefits to research and production. In this study, a generalizable high-throughput relative rAAV titration method is examined within the context of an siRNA screen as siRNA knockdown is a common means of pathway engineering in bioproduction. Crude samples generated from transfected HEK293T/17 cultures were subjected to quantitative PCR (qPCR) and used to transduce COS7 cells to assess relative differences in genomic and infectious rAAV titer, respectively, at the 384-well scale, evaluating both supernatant and lysed samples. To evaluate relevant differences in titer for conditions that could be used in an actual screen, cultures subjected to an siRNA reverse transfection and subsequent rAAV forward transfection were also tested. The delayed forward rAAV triple-plasmid transfection was not seen to affect the siRNA activity of tested controls, while siRNA transfection was shown to measurably impact rAAV titer. Effective differentiation between infectious titer levels was dependent upon the choice of sample dilution, but trends between qPCR and infectious titer assays were consistent across sample sets.
Get full access to this article
View all access options for this article.
References
1.
DrittantiL, RivetC, ManceauP, et al.High throughput production, screening and analysis of adeno-associated viral vectors. Gene Ther, 2000; 7:924–929.
2.
FlotteTR. Revisiting the “new” inflammatory toxicities of adeno-associated virus vectors. Hum Gen Ther, 2020; 31:398–399.
3.
HuangL, WanJ, WuY, et al.Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. Life Sci, 2021; 270:119142.
ClémentN, GriegerJC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev, 2016; 3:16002.
6.
GalibertL, MertenOW. Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases. J Invertebr Pathol, 2011; 107:S80–S93.
7.
StrobelB, ZuckschwerdtK, ZimmermanG, et al.Standardized, scalable, and timely flexible adeno-associated virus vector production using frozen high-density HEK-293 cell stocks and CELLdiscs. Hum Gen Ther Methods, 2019; 30:23–33.
8.
SelvarajN, WangC-K, BowserB, et al.Detailed protocol for the novel and scalable viral vector upstream process for AAV gene therapy manufacturing. Hum Gen Ther, 2021 [Online ahead of print.], DOI: 10.1089/hum.2020.054.
9.
ChahalPS, SchulzeE, TranR, et al.Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery. J Virol Methods, 2014; 196:163–173.
10.
AyusoE, MingozziF, MontaneJ, et al.High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gen Ther, 2010; 17:503–510.
11.
BernaudJ, RossiA, FisA, et al.Characterization of AAV vector particle stability at the single-capsid level. J Biol Phys, 2018; 44:181–194.
12.
BlessingD, VacheyG, PythoudC, et al.Scalable production of AAV vectors in orbitally shaken HEK293 cells. Mol Ther Methods Clin Dev, 2019; 13:14–26.
13.
DobnikD, KogovšekP, JakominT, et al.Accurate quantification and characterization of adeno-associated viral vectors. Front Microbiol, 2019; 10:1570.
14.
NassSA, MattinglyMA, WoodcockDA, et al.Universal method for the purification of recombinant AAV vectors of differing serotypes. Mol Ther Methods Clin Dev, 2017; 9:33–46.
15.
McNallyDJ, PirasBA, WillisCM, et al.Development and optimization of a hydrophobic interaction chromatography-based method of AAV harvest, capture, and recovery. Mol Ther Methods Clin Dev, 2020; 19:275–284.
AdamsB, BakH, TustianAD. Moving from the bench towards a large scale, industrial platform process for adeno-associated viral vector purification. Biotechnol Bioeng, 2020; 117:3199–3211.
18.
QuW, WangM, WuY, et al.Scalable downstream strategies for purification of recombinant adeno-associated virus vectors in light of the properties. Curr Pharm Biotechnol, 2015; 16:684–695.
19.
LockM, AlviraMR, ChenS-J, et al.Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Hum Gen Ther Methods, 2014; 25:115–125.
20.
FrançoisA, BouzelhaM, LecomteE, et al.Accurate titration of infectious AAV particles requires measurement of biologically active vector genomes and suitable controls. Mol Ther Methods Clin Dev, 2018; 10:223–236.
21.
Furuta-HanawaB, YamaguchiT, UchidaE. Two-dimensional droplet digital PCR as a tool for titration and integrity evaluation of recombinant adeno-associated viral vectors. Hum Gen Ther Methods, 2019; 30:127–136.
22.
RaghavanB, CollinsM, Bergheim-PietzaS. Optimization of clarification process for viral vectors. Cytotherapy, 2020; 22:S183–S184.
23.
AndariJE, GrimmD. Production, processing, and characterization of synthetic AAV gene therapy vectors. Biotechnol J, 2021; 16:2000025.
24.
ArunkumarA, SinghN. Ultrafiltration behavior of recombinant adeno associated viral vectors used in gene therapy. J Membr Sci, 2021; 620:118812.
25.
DickersonR, ArgentoC, PieracciJ, et al.Separating empty and full recombinant adeno-associated virus particles using isocratic anion exchange chromatography. Biotechnol J, 2021; 16:2000015.
26.
WrightJF. Product-related impurities in clinical grade recombinant AAV vectors: characterization and risk assessment. Biomedicines, 2014; 2:80–97.
27.
KondratovO, MarsicD, CrossonSM, et al.Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells. Mol Ther, 2017; 25:2661–2675.
28.
WangC, MulagapatiSHR, ChenZ, et al.Developing an anion exchange chromatography assay for determining empty and full capsid contents in AAV6.2. Mol Ther Methods Clin Dev, 2019; 15:257–263.
29.
AiJ, IbraheimR, TaiPWL, et al.Scalable and accurate method for quantifying vector genomes of recombinant adeno-associated viruses in crude lysate. Hum Gen Ther Methods, 2017; 28:139–147.
30.
BinnickerMJ, EspyMJ, IrishCL. Rapid and direct detection of herpes simplex virus in cerebrospinal fluid by use of a commercial real-time PCR assay. J Clin Microbiol, 2014; 52:4361–4362.
31.
KermekchievMB, KirilovaLI, VailEE, et al.Mutants of Taq DNA polymerase resistant to PCR inhibitors allow DNA amplification from whole blood and crude soil samples. Nucleic Acids Res, 2009; 37:e40.
32.
Dias FlorencioG, PrecigoutG, BeleyC, et al.Simple downstream process based on detergent treatment improves yield and in vivo transduction efficacy of adeno-associated virus vectors. Mol Ther Methods Clin Dev, 2015; 2:15024.
33.
ManoM, IppodrinoR, ZentlinL, et al.Genome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction. PNAS, 2015; 112:11276–11281.
34.
WeeSK, SivalingamSP, YapEPH. Rapid direct nucleic acid amplification test without RNA extraction for SARS-Cov-2 using a portable PCR thermocycler. Genes (Basel), 2020; 11:664.
35.
HasanMR, MirzaF, Al-HailH, et al.Detection of SARS-Cov-2 RNA by direct RT-qPCR on nasopharyngeal specimens without extraction of viral RNA. PLoS One, 2020; 15:e0236564.
36.
XuY, GuoP, ZhangJ, et al.Effects of thermally induced configuration changes on rAAV genome's enzymatic accessibility. Mol Ther Methods Clin Dev, 2020; 18:328–334.
37.
WangZ, MaH-L, LiJ, et al.Rapid and highly efficient transduction by double stranded adeno-associated virus vectors in vitro and in vivo. Gen Ther, 2003; 10:2105–2111.
38.
EllisBL, HirschML, MarkerJC, et al.A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J, 2013; 10:74.
39.
BerthetC, RajK, SaudanP, et al.How adeno-associated virus Rep78 protein arrests cells completely in S phase. PNAS, 2005; 102:13634–13639.
40.
YakobsonB, KochT, WinocourE. Replication of adeno-associated virus in synchronized cells without the addition of a helper virus. J Virol, 1987; 61:972–981.
41.
HerrmanA-K, GrimmD. High-throughput dissection of AAV-host interactions: the fast and the curious. J Mol Biol, 2018; 430:2626–2640.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
